相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
Jonathan W. Riess et al.
CLINICAL LUNG CANCER (2021)
Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States
David A. Siegel et al.
JAMA ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Meng Qiao et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
Nasser K. Altorki et al.
LANCET ONCOLOGY (2021)
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Alexander J. Stratigos et al.
LANCET ONCOLOGY (2021)
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Alice Indini et al.
PHARMACEUTICS (2021)
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
VISTA: A Promising Target for Cancer Immunotherapy?
Marco Tagliamento et al.
IMMUNOTARGETS AND THERAPY (2021)
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer
Vassiliki A. Papadimitrakopoulou et al.
CANCER (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Samuel J. Klempner et al.
ONCOLOGIST (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
D. Planchard et al.
ANNALS OF ONCOLOGY (2020)
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Misako Nagasaka et al.
CANCER TREATMENT REVIEWS (2020)
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Jang Ho Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model
Daniel Moldaver et al.
LUNG CANCER (2020)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution
Saioa Lopez et al.
NATURE GENETICS (2020)
Identification of Clonality through Genomic Profile Analysis in Multiple Lung Cancers
Rumi Higuchi et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
Raffaella Pasquale et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Alex Friedlaender et al.
CANCER TREATMENT REVIEWS (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution
Nemanja Despot Marjanovic et al.
CANCER CELL (2020)
Genetic Markers in Lung Cancer Diagnosis: A Review
Katarzyna Wadowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Natural Selection on Exonic SNPs Shapes Allelic Expression Imbalance (AEI) Adaptability in Lung Cancer Progression
Jinfei Huang et al.
FRONTIERS IN GENETICS (2020)
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Xing Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)
M. Hu et al.
ANNALS OF ONCOLOGY (2020)
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
P.A. Jänne et al.
EUROPEAN JOURNAL OF CANCER (2020)
Mechanisms of immune escape in the cancer immune cycle
Sha Tang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Progress of immune checkpoint LAG-3 in immunotherapy
Chanchan Shan et al.
ONCOLOGY LETTERS (2020)
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
Zhangfeng Huang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Immunotherapy and NSCLC: The Long and Winding Road
Antonio Rossi
CANCERS (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Role of SOX Protein Groups F and H in Lung Cancer Progression
Mateusz Olbromski et al.
CANCERS (2020)
Inhibition of Tumor Lymphangiogenesis is an Important Part that EGFR-TKIs Play in the Treatment of NSCLC
Yan Zhang et al.
JOURNAL OF CANCER (2020)
A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy
Keisuke Asakura et al.
COMMUNICATIONS BIOLOGY (2020)
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2019)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
Badi El Osta et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Targeting Alterations in the RAF-MEK Pathway
Rona Yaeger et al.
CANCER DISCOVERY (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma
Ana Galan-Cobo et al.
CANCER RESEARCH (2019)
Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study
Angela R. Shih et al.
HISTOPATHOLOGY (2019)
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular and Morphological Profiling of Lung Cancer: A Foundation for Next-Generation Pathologists and Oncologists
Jumpei Kashima et al.
CANCERS (2019)
Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity
Natasha Rekhtman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
Mark M. Awad et al.
LUNG CANCER (2019)
Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?
Hira Latif et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale
Jillian Wilhelmina Paulina Bracht et al.
CANCERS (2019)
1197PA phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
A Spreafico et al.
ANNALS OF ONCOLOGY (2019)
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P. Robichaux et al.
CANCER CELL (2019)
EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC
M. Gogishvili et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Ryohei Katayama et al.
NATURE COMMUNICATIONS (2019)
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y. Wang et al.
ANNALS OF ONCOLOGY (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer
Keyi Jia et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Accumulation of genetic and epigenetic alterations in normal cells and cancer risk
Hideyuki Takeshima et al.
NPJ PRECISION ONCOLOGY (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Applications and analysis of targeted genomic sequencing in cancer studies
Findlay Bewicke-Copley et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Global Epidemiology of Lung Cancer
Julie A. Barta et al.
ANNALS OF GLOBAL HEALTH (2019)
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
S. Novello et al.
ANNALS OF ONCOLOGY (2018)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers
Kazuki Takada et al.
CLINICAL LUNG CANCER (2018)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Tejas Patil et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Irene Ferrer et al.
LUNG CANCER (2018)
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Marta Roman et al.
MOLECULAR CANCER (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
Sanjay Popat
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Aging and the rise of somatic cancer-associated mutations in normal tissues
Rosa Ana Risques et al.
PLOS GENETICS (2018)
Clinically Correlated MicroRNAs in the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Min Jiang et al.
BIOMED RESEARCH INTERNATIONAL (2018)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?
Shinji Atagi
JOURNAL OF THORACIC ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
LBA6Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
N A Rizvi et al.
ANNALS OF ONCOLOGY (2018)
LBA65IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC
M A Socinski et al.
ANNALS OF ONCOLOGY (2018)
LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
F Cappuzzo et al.
ANNALS OF ONCOLOGY (2018)
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
Kaikai Shen et al.
JOURNAL OF THORACIC DISEASE (2018)
IMpower132: PFS and Safety Results with 1L Atezolizumab plus Carboplatin/Cisplatin plus Pemetrexed in Stage IV Non-Squamous NSCLC
V. Papadimitrakopoulou et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer
Le-Le Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Myung-Ju Ahn et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
Sun Min Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer
Sara Baglivo et al.
MAYO CLINIC PROCEEDINGS (2017)
A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
Guanghui Cui et al.
MEDICINE (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Epigenetics and Oxidative Stress in Aging
Amy Guillaumet-Adkins et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Epigenetic plasticity and the hallmarks of cancer
William A. Flavahan et al.
SCIENCE (2017)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
M. G. Kris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Rathi N. Pillai et al.
CANCER (2017)
European cancer mortality predictions for the year 2017, with focus on lung cancer
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer
Shawn M. Davidson et al.
CELL METABOLISM (2016)
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review
Yen-Ting Lin et al.
CLINICAL LUNG CANCER (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Drilon et al.
LANCET ONCOLOGY (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Clinical Implications of Genomic Discoveries in Lung Cancer
Charles Swanton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma
Anna Biernacka et al.
CANCER GENETICS (2016)
Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
Coureche Guillaume Kaderbhai et al.
ONCOTARGET (2016)
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Lung Cancer in the Era of Precision Medicine
Katerina Politi et al.
CLINICAL CANCER RESEARCH (2015)
The Structural Characterization of Tumor Fusion Genes and Proteins
Dandan Wang et al.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2015)
Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988-2010
Joannie Lortet-Tieulent et al.
EUROPEAN JOURNAL OF CANCER (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Cell-of-origin chromatin organization shapes the mutational landscape of cancer
Paz Polak et al.
NATURE (2015)
Refining the treatment of NSCLC according to histological and molecular subtypes
Anish Thomas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Activation of RAS family members confers resistance to ROS1 targeting drugs
Marilisa Cargnelutti et al.
ONCOTARGET (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973-2010
Rafael Meza et al.
PLOS ONE (2015)
Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer From SEER Registries: AJCC Staging and Collaborative Stage Data Collection System
Vivien W. Chen et al.
CANCER (2014)
Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing
Carolyn J. Shiau et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Challenges to effective cancer control in China, India, and Russia
Paul E. Goss et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang et al.
SCIENCE (2014)
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Elza C. de Bruin et al.
SCIENCE (2014)
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Causes of Genome Instability
Andres Aguilera et al.
ANNUAL REVIEW OF GENETICS, VOL 47 (2013)
Genome Instability and Aging
Jan Vijg et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 75 (2013)
Interplay between the Cancer Genome and Epigenome
Hui Shen et al.
CELL (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
William D. Travis et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE)
Ole Raaschou-Nielsen et al.
LANCET ONCOLOGY (2013)
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Larissa A. Pikor et al.
LUNG CANCER (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Steven A. Roberts et al.
NATURE GENETICS (2013)
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi et al.
NATURE MEDICINE (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
50-Year Trends in Smoking-Related Mortality in the United States
Michael J. Thun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
PLOS ONE (2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Bengt Hallberg et al.
NATURE REVIEWS CANCER (2013)
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
Yibing Shan et al.
CELL (2012)
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Victoria M. Rimkunas et al.
CLINICAL CANCER RESEARCH (2012)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Correction: Serum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer
Patrick T. Hennessey et al.
PLoS One (2012)
Long-term Ambient Fine Particulate Matter Air Pollution and Lung Cancer in a Large Cohort of Never-Smokers
Michelle C. Turner et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
Yelena Y. Janjigian et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
Denise R. Aberle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Somatic mosaicism in healthy human tissues
Subhajyoti De
TRENDS IN GENETICS (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evidence for Common Clonal Origin of Multifocal Lung Cancers
Xiaoyan Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Multifocal Lung Cancers-025EFClonality vs Field Cancerization and Does It Matter?
Adi F. Gazdar et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Defining 'chromosomal instability'
Jochen B. Geigl et al.
TRENDS IN GENETICS (2008)
Hypoxia, DNA repair and genetic instability
Robert G. Bristow et al.
NATURE REVIEWS CANCER (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs
Mayumi Ono et al.
CLINICAL CANCER RESEARCH (2006)
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
DW Bell et al.
NATURE GENETICS (2005)
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma
ES Kim et al.
CANCER (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease
RG Zinner et al.
LUNG CANCER (2004)
Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms
JL Arbiser
SEMINARS IN CANCER BIOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase II study of the farnesyl transferase inhibitor r115777 in patients with advanced non-small-cell lung cancer
AA Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The clinical importance and prognostic implications of microsatellite instability in sporadic cancer
DA Lawes et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling
XC Yu et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Cancer causation: the Darwinian downside of past success?
M Greaves
LANCET ONCOLOGY (2002)
分享论文
